AU2003272007A1 - Use of n-5-4-(4-methylpiperaziomethyl)-benzoylamido!-2-methylphenyl!-4-(3-pyridyl)2-pyridine-amine for the treatment of pulmonary hypertension - Google Patents

Use of n-5-4-(4-methylpiperaziomethyl)-benzoylamido!-2-methylphenyl!-4-(3-pyridyl)2-pyridine-amine for the treatment of pulmonary hypertension

Info

Publication number
AU2003272007A1
AU2003272007A1 AU2003272007A AU2003272007A AU2003272007A1 AU 2003272007 A1 AU2003272007 A1 AU 2003272007A1 AU 2003272007 A AU2003272007 A AU 2003272007A AU 2003272007 A AU2003272007 A AU 2003272007A AU 2003272007 A1 AU2003272007 A1 AU 2003272007A1
Authority
AU
Australia
Prior art keywords
methylpiperaziomethyl
benzoylamido
methylphenyl
pyridyl
pyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003272007A
Other languages
English (en)
Inventor
Joseph Alexander Lasky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tulane University
Original Assignee
Tulane University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tulane University filed Critical Tulane University
Publication of AU2003272007A1 publication Critical patent/AU2003272007A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2003272007A 2002-10-25 2003-10-20 Use of n-5-4-(4-methylpiperaziomethyl)-benzoylamido!-2-methylphenyl!-4-(3-pyridyl)2-pyridine-amine for the treatment of pulmonary hypertension Abandoned AU2003272007A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42131802P 2002-10-25 2002-10-25
US60/421,318 2002-10-25
PCT/IB2003/004671 WO2004037261A1 (en) 2002-10-25 2003-10-20 Use of n-‘5-‘4-(4-methylpiperaziomethyl)-benzoylamido!-2-methylphenyl!-4-(3-pyridyl)2-pyridine-amine for the treatment of pulmonary hypertension

Publications (1)

Publication Number Publication Date
AU2003272007A1 true AU2003272007A1 (en) 2004-05-13

Family

ID=32176700

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003272007A Abandoned AU2003272007A1 (en) 2002-10-25 2003-10-20 Use of n-5-4-(4-methylpiperaziomethyl)-benzoylamido!-2-methylphenyl!-4-(3-pyridyl)2-pyridine-amine for the treatment of pulmonary hypertension

Country Status (4)

Country Link
US (3) US20060154936A1 (cg-RX-API-DMAC7.html)
JP (1) JP4942297B2 (cg-RX-API-DMAC7.html)
AU (1) AU2003272007A1 (cg-RX-API-DMAC7.html)
WO (1) WO2004037261A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040167134A1 (en) * 2001-05-16 2004-08-26 Christian Bruns Combination comprising n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent
AU2003244922A1 (en) * 2002-06-28 2004-01-19 The Administrators Of The Tulane Educational Fund 4-(4-methylpiperazin-1-ylmethyl)-n-(4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl)-benzamide for treating pulmonary fibrosis
CN101203224B (zh) * 2005-01-28 2010-11-03 诺瓦提斯公司 嘧啶基氨基苯甲酰胺在制备治疗对Tie-2激酶活性的调节有响应的疾病的药物中的用途
EP1741432A1 (de) * 2005-07-07 2007-01-10 Universitätsklinikum Freiburg Tyrosinkinase-Inhibitor Imatinib zur Behandlung von Bluthochdruck
RU2431484C2 (ru) * 2005-11-10 2011-10-20 Байер Шеринг Фарма Акциенгезельшафт Диарилмочевина для лечения легочной гипертензии
EP2170306A1 (en) * 2007-06-26 2010-04-07 Lexicon Pharmaceuticals, Inc. Methods of treating serotonin-mediated diseases and disorders
US7875622B2 (en) 2007-07-11 2011-01-25 Lexicon Pharmaceuticals, Inc. Methods and compositions for treating pulmonary hypertension and related diseases and disorders
WO2010019540A1 (en) * 2008-08-13 2010-02-18 Novartis Ag Treatment of pulmonary arterial hypertension
AU2014205483B2 (en) 2013-01-10 2017-11-30 Gilead Sciences, Inc. Non-selective kinase inhibitors
EP3054937B1 (en) 2013-10-11 2023-07-26 Pulmokine, Inc. Spray dry formulations
WO2018081567A1 (en) 2016-10-27 2018-05-03 Pulmokine, Inc. Combination therapy for treating pulmonary hypertension
KR20190005708A (ko) * 2017-07-05 2019-01-16 이화여자대학교 산학협력단 에피디티오디옥소피페라진 화합물 또는 이의 유도체, 또는 이들의 약학적으로 허용가능한 염을 포함하는 폐동맥고혈압 예방 또는 치료용 약학적 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
EP1337557A2 (en) * 2000-11-28 2003-08-27 Mondobiotech SA Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension
AU2003233946A1 (en) * 2002-03-15 2003-09-29 Novartis Ag 4-(4-methylpiperazin-1-ylmethyl)-n-(4-methyl-3(4-pyridin-3-yl)pyrimidin-2-yl-amino)phenyl)-benzamide for treating ang ii-mediated diseases

Also Published As

Publication number Publication date
US20120214819A1 (en) 2012-08-23
US20060154936A1 (en) 2006-07-13
JP4942297B2 (ja) 2012-05-30
WO2004037261A1 (en) 2004-05-06
US20110046150A1 (en) 2011-02-24
JP2006505582A (ja) 2006-02-16

Similar Documents

Publication Publication Date Title
IL178786A0 (en) Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension
IL164533A0 (en) Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds
ZA200700223B (en) Quinazolin-4-yl-piperidine and cinnolin-4-yl-peperidine derivatives as PDE10 inhibitors for the treatment of CNS disorders
NO20044905L (no) Fremgangsmate for rullesliping
AP2003002857A0 (en) New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors.
IL161516A0 (en) Benzimidazoles useful as protein kinase inhibitors
AU2003238561A1 (en) Compositions and methods for treating gynaecological disorders
AU2002338807A1 (en) Use of c-kit inhibitors for the treatment of myeloma
AU2003219100A1 (en) Pyrazolopyridazine derivatives, process for preparation and use for the inhibition of gsk-3
AU2003272007A1 (en) Use of n-5-4-(4-methylpiperaziomethyl)-benzoylamido!-2-methylphenyl!-4-(3-pyridyl)2-pyridine-amine for the treatment of pulmonary hypertension
AU2003293099A1 (en) Treatment of dna damage related disorders
EP1610798A4 (en) ESTRADIOL METABOLITES FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION
IL161748A0 (en) New use for the treatment of gastroesophageal reflux
SI2366393T1 (sl) Roflumilast za zdravljenje pljučne hipertenzije
AU2002350832A1 (en) Use of irbesartan for the preparation of medicaments that are used to prevent or treat pulmonary hypertension
AU2003220026A1 (en) Methods and compositions for the treatment of ischemia
GB2410744B (en) Kinase inhibitors for the treatment of disease
AU2003274885A1 (en) Phenyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain or gastrointestinal disorders
AU2003243214A1 (en) Salts of bis-arylsulfones for the treatment of cns disorders
AU2003240174A8 (en) Compositions for the treatment of edematous-firbrosclerotic panniculopathy
AU2003289889A1 (en) Methods for the treatment of alzheimers disease and compositions therefore
AU2002366272A8 (en) Edg-receptor agonist for the treatment of hypertension
GB0304021D0 (en) Treatment of hypertension
HK1108120A (en) Methods and compositions for the treatment of pulmonary hypertension of the newborn
IL179092A0 (en) Spiroderivatives for the treatment of hypertension

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase